US · NRIX
Nurix Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Francisco, CA 94158
- Website
- nurixtx.com
Price · as of 2025-11-30
$16.81
Market cap 1.38B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $26.29 | +56.4% |
| Intrinsic Value(DCF) | $8.20 | -51.22% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $4.54 | |||
| 2020 | $38.78 | $108.54 | $13.24 | $4.72 | $90.52 |
| 2021 | $18.20 | $1,047.93 | $4.85 | $0.00 | $0.00 |
| 2022 | $11.65 | $16.59 | $2.30 | $0.00 | $0.00 |
| 2023 | $8.85 | $32.07 | $261.17 | $0.00 | $0.00 |
| 2024 | $18.88 | $23.23 | $4.33 | $0.00 | $57.10 |
| 2025 | $16.85 | $26.29 | $2.48 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Nurix Therapeutics, Inc.'s (NRIX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $26.29
- Current price
- $16.81
- AI upside
- +56.4%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.20
-51.22% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NRIX | Nurix Therapeutics, Inc. | $16.81 | 1.38B | +56% | -51% | — | — | -5.52 | 2.71 | 17.39 | -3.77 | -93.55 | 2.71 | 77.55% | -340.16% | -314.90% | -49.63% | 1083.07% | -38.96% | 0.10 | — | 7.02 | 6.86 | 0.78 | 590.00% | 5395.00% | 4488.00% | -18.04% | -2.88 | 998.91% | 0.00% | 0.00% | 7.50% | -3.23 | -3.50 | 10.99 | 3.48 |
| BBOT | BridgeBio Oncology Therap… | $10.03 | 802.29M | — | — | — | — | 23.73 | 0.96 | — | -2.21 | — | 0.96 | 0.00% | — | — | 8.06% | -86.47% | 7.80% | 0.00 | — | 10.40 | 9.05 | 0.02 | -2310000.00% | — | — | -0.42% | -4.07 | -0.82% | 0.00% | 0.00% | 0.98% | -2.21 | -233.87 | — | 17.57 |
| EYPT | EyePoint Pharmaceuticals,… | $17.56 | 1.45B | +9,195% | -75% | — | — | -3.07 | 1.19 | 9.28 | -0.41 | -11.16 | 1.19 | 91.42% | -337.06% | -302.43% | -43.42% | 403.05% | -33.83% | 0.06 | -10418.14 | 7.81 | 7.57 | 0.60 | 2747.00% | -597.00% | 800187.00% | -32.46% | -2.57 | 360.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 1.21 | -0.07 |
| FTRE | Fortrea Holdings Inc. | $10.72 | 990.53M | +1% | -61% | — | — | -0.98 | 1.71 | 0.35 | -1.05 | -0.50 | -0.95 | 15.63% | -32.04% | -36.21% | -102.41% | -60.19% | -31.33% | 0.12 | -9.55 | 0.98 | 0.84 | 0.13 | 19455.00% | 100.00% | -6279.00% | 9.17% | 0.12 | 6.09% | 0.00% | 0.00% | 123.21% | -0.98 | 9.70 | 0.31 | -0.51 |
| KOD | Kodiak Sciences Inc. | $26.80 | 1.42B | — | — | — | — | -1.08 | 1.27 | — | -0.62 | — | 1.27 | 0.00% | — | — | -84.70% | -174.25% | -43.24% | 0.47 | — | 6.72 | 6.57 | 0.65 | -3260.00% | — | -3982.00% | -61.84% | -4.59 | -109.78% | 0.00% | 0.00% | 0.00% | -0.50 | -0.79 | — | -6.24 |
| KURA | Kura Oncology, Inc. | $8.73 | 759.66M | — | — | — | — | -3.73 | 1.57 | 12.04 | 0.37 | — | 1.57 | 100.00% | -358.55% | -322.89% | -42.91% | 126.01% | -28.78% | 0.04 | -119.33 | 9.46 | 9.24 | 1.23 | -288.00% | — | -20708.00% | 20.63% | 1.71 | -87.30% | 0.00% | 0.00% | 28.94% | 0.32 | -0.46 | -1.15 | -0.24 |
| PHAT | Phathom Pharmaceuticals, … | $12.56 | 979.85M | +275% | +76,266% | — | — | -3.78 | -1.91 | 4.77 | -4.45 | — | -1.91 | 87.09% | -91.36% | -126.35% | 63.97% | 57.00% | -69.41% | -0.01 | -2.35 | 1.73 | 1.58 | 0.80 | -4272.00% | 21693.00% | -3743.00% | -19.98% | -1.26 | 59.50% | 0.00% | 0.00% | 46.07% | -4.43 | -4.24 | 4.05 | -8.21 |
| SEPN | Septerna, Inc. | $29.02 | 1.3B | +1,403% | -60% | -79% | — | -0.89 | 0.15 | 59.16 | 3.30 | — | 0.15 | 100.00% | -7518.42% | -6678.88% | -37.62% | 815.26% | -24.45% | 0.06 | — | 27.77 | 27.40 | 2.68 | -2504845.00% | 61192.00% | 6724.00% | -109.39% | -5.25 | 706.65% | 0.00% | 0.00% | 215.10% | 3.24 | 3.76 | -243.58 | 1.00 |
| TNGX | Tango Therapeutics, Inc. | $11.14 | 1.23B | +109% | +24,801% | — | — | -1.68 | 1.10 | 5.22 | 0.01 | -16.54 | 1.10 | 100.00% | -346.09% | -309.73% | -57.58% | 436.15% | -36.24% | 0.18 | — | 6.98 | 6.76 | 0.23 | 1019.00% | 1517.00% | 1067.00% | -60.24% | -3.45 | 396.19% | 0.00% | 0.00% | 2.54% | 0.01 | 0.01 | -0.04 | -1.61 |
| URGN | UroGen Pharma Ltd. | $21.70 | 1.02B | -0% | -82% | — | — | -3.32 | -47.83 | 4.66 | -3.23 | — | -47.83 | 90.18% | -107.06% | -140.35% | 342.83% | 86.07% | -54.68% | -14.02 | -7.73 | 6.01 | 5.59 | 0.51 | -1662.00% | 929.00% | 2676.00% | -23.05% | -2.11 | 86.32% | 0.00% | 0.00% | 12.59% | -3.18 | -3.17 | 3.40 | -2.93 |
| XNCR | Xencor, Inc. | $12.77 | 911.91M | +93% | -51% | -81% | — | -9.93 | 1.44 | 7.27 | -15.55 | — | 1.46 | 91.63% | -141.35% | -73.20% | -14.00% | -41.06% | -10.06% | 0.40 | -5.56 | 6.25 | 4.84 | -4.22 | -6536.00% | 1365.00% | -3362.00% | -15.14% | -1.41 | -31.98% | 0.00% | 0.00% | 0.00% | -4.11 | -5.28 | 5.82 | 1.18 |
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
- CEO
- Arthur T. Sands
- Employees
- 286
- Beta
- 1.97
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.20 ÷ $16.81) − 1 = -51.22% (DCF, example).